Thursday, November 6, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Groupon Shares Surge as Analysts Issue Bullish Upgrades

Robert Sasse by Robert Sasse
September 21, 2025
in Analysis, E-Commerce, Nasdaq
0
Groupon Stock
0
SHARES
52
VIEWS
Share on FacebookShare on Twitter

Groupon shares concluded Friday’s trading session with modest gains, fluctuating between $22.52 and $22.66. This positive movement suggests potential stabilization following a period of weaker weekly performance.

Significant Price Target Revisions Fuel Momentum

Market analysts have demonstrated renewed confidence in the deal platform operator through substantial upward revisions. Roth Capital elevated its price objective from $33 to $47, while Northland Securities increased its target from $39 to $44. The collective consensus price target now stands at $29.80.

Further reinforcing this optimistic outlook, the Zacks Consensus Estimate for Groupon’s full-year earnings per share has been revised upward by a remarkable 31.1% over the past month, now projecting $0.80. This overwhelming analyst endorsement has earned Groupon the prestigious Zacks Rank #1 (Strong Buy) designation.

Strong Quarterly Performance Underpins Confidence

The company’s recent quarterly report, released on August 6, substantially exceeded market expectations. Rather than reporting an anticipated loss of $0.02 per share, Groupon announced a profit of $0.46 per share. Revenue performance also surpassed forecasts, with actual figures reaching $125.70 million compared to the projected $122.46 million.

Should investors sell immediately? Or is it worth buying Groupon?

Institutional Investment Signals Growing Interest

Adding to the positive indicators, Range Financial Group LLC established a significant position during the second quarter, investing $1.26 million to acquire 37,764 Groupon shares. Such institutional accumulation typically reflects well-researched conviction in a company’s prospects.

From a technical analysis perspective, the equity generated a buy signal from a bottom formation on Wednesday. Friday’s trading session provided additional confirmation for bullish investors through increased trading volume accompanied by price appreciation.

Despite these encouraging developments, moving averages continue to indicate potential resistance levels. The stock’s weekly performance through September 19 remained subdued, showing a decline of 1.36%.

Market participants now await Groupon’s next earnings announcement scheduled for November 11. Current analyst consensus maintains a “Moderate Buy” recommendation with the $29.80 average price target suggesting substantial potential upside from current trading levels.

Ad

Groupon Stock: Buy or Sell?! New Groupon Analysis from November 6 delivers the answer:

The latest Groupon figures speak for themselves: Urgent action needed for Groupon investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 6.

Groupon: Buy or sell? Read more here...

Tags: Groupon
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

DuPont de Nemours Stock
Analysis

DuPont Faces Critical Test as Quarterly Results Loom

November 6, 2025
Sarepta Therapeutics Stock
Analysis

Sarepta Therapeutics Shares Plummet Following Critical Clinical Trial Failure

November 6, 2025
Darden Restaurants Stock
Analysis

Is Darden Restaurants Facing a Critical Test?

November 6, 2025
Next Post
Century Therapeutics Stock

Is Century Therapeutics Stock a High-Stakes Turnaround Play?

Union Pacific Stock

Political Backing Fuels Speculation Over Major Railroad Merger

Waterstone Stock

Waterstone Financial Shares Show Resilience Amid Sector Volatility

Recommended

Baidu Stock

Baidu’s Strategic Moves in Autonomous Driving and AI Draw Mixed Investor Reactions

1 month ago

Windtree Therapeutics Achieves Financial Stability and Advances Clinical Programs

2 years ago
Technology Data analytics Stock Bull Market

Anticipation High for Adobes FirstQuarter Financial Results and AI Innovation

2 years ago
Ideaya Biosciences Stock

Ideaya Biosciences: A Tale of Market Skepticism and Clinical Promise

2 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

EU Grant Provides Critical Boost for LanzaTech’s Carbon Recycling Technology

Is Darden Restaurants Facing a Critical Test?

Critical Juncture for USA Rare Earth as Earnings and Chinese Export Curbs Collide

AES Shares Surge on Potential $38 Billion Acquisition Speculation

Kura Oncology Investors Await Crucial FDA Verdict

Cadence Design Stock: A Battle Between Fundamentals and Market Signals

Trending

DuPont de Nemours Stock
Analysis

DuPont Faces Critical Test as Quarterly Results Loom

by Dieter Jaworski
November 6, 2025
0

DuPont de Nemours finds itself at a pivotal moment as the chemical giant prepares to release quarterly...

Sarepta Therapeutics Stock

Sarepta Therapeutics Shares Plummet Following Critical Clinical Trial Failure

November 6, 2025
Emerson Electric Stock

Emerson Electric’s Strategic Pivot Faces Market Scrutiny

November 6, 2025
Lanzatech Global Stock

EU Grant Provides Critical Boost for LanzaTech’s Carbon Recycling Technology

November 6, 2025
Darden Restaurants Stock

Is Darden Restaurants Facing a Critical Test?

November 6, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • DuPont Faces Critical Test as Quarterly Results Loom
  • Sarepta Therapeutics Shares Plummet Following Critical Clinical Trial Failure
  • Emerson Electric’s Strategic Pivot Faces Market Scrutiny

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com